Literature DB >> 21893542

Contribution of vaccines to our understanding of pneumococcal disease.

Keith P Klugman1.   

Abstract

Pneumonia is the leading cause of mortality in children in developing countries and is also the leading infectious cause of death in adults. The most important cause of pneumonia is the Gram-positive bacterial pathogen, Streptococcus pneumoniae, also known as the pneumococcus. It has thus become the leading vaccine-preventable cause of death and is a successful and diverse human pathogen. The development of conjugate pneumococcal vaccines has made possible the prevention of pneumococcal disease in infants, but has also elucidated aspects of pneumococcal biology in a number of ways. Use of the vaccine as a probe has increased our understanding of the burden of pneumococcal disease in children globally. Vaccination has also elucidated the clinical spectrum of vaccine-preventable pneumococcal infections; the identification of a biological niche for multiple pneumococcal serotypes in carriage and the differential invasiveness of pneumococcal serotypes; the impact of pneumococcal transmission among children on disease burden in adults; the role of carriage as a precursor to pneumonia; the plasticity of a naturally transformable pathogen to respond to selective pressure through capsular switching and the accumulation of antibiotic-resistance determinants; and the role of pneumococcal infections in hospitalization and mortality associated with respiratory viral infections, including both seasonal and pandemic influenza. Finally, there has been a recent demonstration that pneumococcal pneumonia in children may be an important cause of hospitalization for those with underlying tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21893542      PMCID: PMC3146770          DOI: 10.1098/rstb.2011.0032

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  65 in total

1.  Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era.

Authors:  Robert E Gertz; Zhongya Li; Fabiana C Pimenta; Delois Jackson; Billie A Juni; Ruth Lynfield; James H Jorgensen; Maria da Gloria Carvalho; Bernard W Beall
Journal:  J Infect Dis       Date:  2010-03       Impact factor: 5.226

2.  The "Achilles heel" of global efforts to combat infectious diseases.

Authors:  Ruth Berkelman; Gail Cassell; Steven Specter; Margaret Hamburg; Keith Klugman
Journal:  Clin Infect Dis       Date:  2006-05-15       Impact factor: 9.079

3.  Holiday spikes in pneumococcal disease among older adults.

Authors:  Nicholas D Walter; Thomas H Taylor; Scott F Dowell; Saundra Mathis; Matthew R Moore
Journal:  N Engl J Med       Date:  2009-12-24       Impact factor: 91.245

4.  Carriage of pneumococci after pneumococcal vaccination.

Authors:  S K Obaro; R A Adegbola; W A Banya; B M Greenwood
Journal:  Lancet       Date:  1996-07-27       Impact factor: 79.321

5.  Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia.

Authors:  Andrew Jardine; Robert I Menzies; Peter B McIntyre
Journal:  Pediatr Infect Dis J       Date:  2010-07       Impact factor: 2.129

6.  The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children.

Authors:  Shabir A Madhi; Locadiah Kuwanda; Clare Cutland; Keith P Klugman
Journal:  Clin Infect Dis       Date:  2005-04-07       Impact factor: 9.079

7.  GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis.

Authors:  Ying-Jie Lu; Luciana Leite; Viviane Maimoni Gonçalves; Waldely de Oliveira Dias; Celia Liberman; Fernando Fratelli; Mark Alderson; Andrea Tate; Jean-François Maisonneuve; George Robertson; Rita Graca; Sabina Sayeed; Claudette M Thompson; Porter Anderson; Richard Malley
Journal:  Vaccine       Date:  2010-09-19       Impact factor: 3.641

8.  Influenza alone and in sequence with pneumonia due to Streptococcus pneumoniae in the squirrel monkey.

Authors:  R F Berendt; G G Long; J S Walker
Journal:  J Infect Dis       Date:  1975-12       Impact factor: 5.226

9.  Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor.

Authors:  Jonathan A McCullers; Jerold E Rehg
Journal:  J Infect Dis       Date:  2002-07-10       Impact factor: 5.226

10.  Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa.

Authors:  P M Jeena; P Pillay; T Pillay; H M Coovadia
Journal:  Int J Tuberc Lung Dis       Date:  2002-08       Impact factor: 2.373

View more
  15 in total

Review 1.  Recent advances in pneumococcal peptidoglycan biosynthesis suggest new vaccine and antimicrobial targets.

Authors:  Lok-To Sham; Ho-Ching T Tsui; Adrian D Land; Skye M Barendt; Malcolm E Winkler
Journal:  Curr Opin Microbiol       Date:  2012-01-24       Impact factor: 7.934

Review 2.  Influence of bacterial interactions on pneumococcal colonization of the nasopharynx.

Authors:  Joshua R Shak; Jorge E Vidal; Keith P Klugman
Journal:  Trends Microbiol       Date:  2012-12-25       Impact factor: 17.079

3.  Vaccines and global health.

Authors:  Brian Greenwood; David Salisbury; Adrian V S Hill
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-12       Impact factor: 6.237

4.  Streptococcus pneumoniae pharyngeal colonization in school-age children and adolescents with cancer.

Authors:  Nicola Principi; Valentina Preti; Stefania Gaspari; Antonella Colombini; Marco Zecca; Leonardo Terranova; Maria Giuseppina Cefalo; Valentina Ierardi; Claudio Pelucchi; Susanna Esposito
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

5.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321

6.  Effect of age and vaccination with a pneumococcal conjugate vaccine on the density of pneumococcal nasopharyngeal carriage.

Authors:  A Roca; C Bottomley; P C Hill; A Bojang; U Egere; M Antonio; O Darboe; B M Greenwood; R A Adegbola
Journal:  Clin Infect Dis       Date:  2012-06-14       Impact factor: 9.079

7.  Variation in Streptococcus pneumoniae susceptibility to human antimicrobial peptides may mediate intraspecific competition.

Authors:  Michelle G J L Habets; Daniel E Rozen; Michael A Brockhurst
Journal:  Proc Biol Sci       Date:  2012-07-04       Impact factor: 5.349

8.  Novel Strategy To Protect against Influenza Virus-Induced Pneumococcal Disease without Interfering with Commensal Colonization.

Authors:  Christopher J Greene; Laura R Marks; John C Hu; Ryan Reddinger; Lorrie Mandell; Hazeline Roche-Hakansson; Natalie D King-Lyons; Terry D Connell; Anders P Hakansson
Journal:  Infect Immun       Date:  2016-05-24       Impact factor: 3.441

9.  Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial.

Authors:  Menno R van den Bergh; Judith Spijkerman; Kristien M Swinnen; Nancy A François; Thierry G Pascal; Dorota Borys; Lode Schuerman; Ed P F Ijzerman; Jacob P Bruin; Arie van der Ende; Reinier H Veenhoven; Elisabeth A M Sanders
Journal:  Clin Infect Dis       Date:  2012-11-01       Impact factor: 9.079

10.  High prevalence of antibiotic resistance in nasopharyngeal bacterial isolates from healthy children in rural Uganda: A cross-sectional study.

Authors:  Elizeus Rutebemberwa; Betty Mpeka; George Pariyo; Stefan Peterson; Edison Mworozi; Freddie Bwanga; Karin Källander
Journal:  Ups J Med Sci       Date:  2015-08-25       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.